Haemonetics (HAE) Stock: Buy, Sell, or Hold?
HAE - Haemonetics Corporation
$117.11
-1.10 (-0.93%)
âŧ
5d:
-3.3%
30d:
+7.92%
90d:
+51.3%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 05, 2026
13d
Get Alerted When HAE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: HAE is fairly priced but lacks strong directional signals. At 14.7% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: HAE is fairly priced but lacks strong directional signals. At 14.7% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$101.63
Based on 5.5% avg growth
INTRINSIC VALUE TODAY
$63.11
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HAE is currently trading at $117.11, which is considered slightly high relative to its 30-day fair value range of $103.99 to $117.63. From a valuation perspective, the stock is trading at a premium (Forward PE: 22.1) compared to its historical average (14.7). At these levels, the market is pricing in 14.7% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, HAE is in a strong uptrend. Immediate support is located at $111.66, while resistance sits at $123.77.
Market Sentiment: HAE scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HAE is in a strong uptrend. Immediate support is located at $111.66, while resistance sits at $123.77.
Market Sentiment: HAE scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$103.99 -
$117.63
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
33.3%
All Signals
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($124.50)
- BEARISH: Market expects 14.7% growth - appears too optimistic based on history
- WARNING: Composite score 35/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$103.99 -
$117.63
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$111.66
Resistance Level
$123.77
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
22.13
Wall Street Target
$124.50
(+6.3%)
Revenue Growth (YoY)
5.6%
Earnings Growth (YoY)
2.9%
Profit Margin
7.1%
Valuation Premium vs History
+14.7% premium
PE vs Historical
22.1 vs 14.7
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+14.7%
(market-implied from PE analysis)
1-Year Target
$134.33
(+15%)
2-Year Target
$154.07
(+32%)
3-Year Target
$176.72
(+51%)
3-Yr Target (if PE normalizes)
(PE: 22â15)
PE COMPRESSION
$117.38
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 7.0%)
$143.63
(+23%)
Base:
(SPY PE: 19.9, Growth: 7.0%)
$128.89
(+10%)
Bear:
(PE: 14.7, Growth: 7.0%)
$95.40
(-19%)
đ
Valuation based on Current Earnings
Forward PE: 20.33 | Forward EPS (Implied): $5.76
Bull Case
$141.41
(+21%)
Analyst growth 15.0%, PE expands to 21.3
Base Case
$117.11
(0%)
Market implied 0.0%, PE stable at 20.3
Bear Case
$89.59
(-24%)
Severe decline -15.0%, PE contracts to 18.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 21, 2026 7:06 PM ET
Data refreshes hourly during market hours. Next update: 8:06 PM
Data refreshes hourly during market hours. Next update: 8:06 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HAE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
29 analysts |
$96 | 50 HOLD |
|
EW
Edwards Lifesciences Corp |
STRONG BUY
29 analysts |
$102 | 59 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
28 analysts |
$121 | 53 HOLD |
|
SYK
Stryker Corporation |
STRONG BUY
29 analysts |
$363 | 37 SELL |
|
CATX
Perspective TherapeuticsâĻ |
STRONG BUY
14 analysts |
$12 | 60 HOLD |
